Lisinopril is an angiotensin-converting enzyme inhibitor used in formulations targeting essential hypertension, renovascular hypertension, and symptomatic heart failure. By suppressing the conversion of angiotensin I to angiotensin II, it reduces plasma angiotensin II levels, decreases vasopressor activity, and lowers aldosterone secretion. Production adheres to current Good Manufacturing Practice guidelines, ensuring precise assay compliance and consistent solid-state properties suitable for direct compression and wet granulation tableting processes.
Product Information
|
Parameter |
Specification Details |
|
International Nonproprietary Name |
Lisinopril |
|
Chemical Name |
(S)-1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline dihydrate |
|
CAS Registry Number |
83915-83-9 |
|
Molecular Formula |
C21H31N3O5 |
|
Molecular Weight |
405.49 g/mol |
|
Structural Class |
Dicarboxylate-containing ACE inhibitor |
|
Pharmacopeial Compliance |
USP / EP / BP |
|
Storage Conditions |
Store in tight containers at 15°C to 30°C, protected from moisture and light |
|
Shelf Life |
36 months from the date of manufacture |
Quality and Specification
|
Test Parameter |
Acceptance Criteria |
|
Description |
White or almost white, crystalline powder |
|
Solubility |
Sparingly soluble in water, freely soluble in methanol, practically insoluble in ethanol |
|
Identification |
Infrared absorption spectrum matches reference standard; retention time conforms to reference solution |
|
Specific Optical Rotation |
-47.0° to -52.0° calculated on the anhydrous substance |
|
Water Content |
8.5% to 10.5% determined by Karl Fischer titration |
|
Residue on Ignition |
Maximum 0.1% |
|
Heavy Metals |
Maximum 10 ppm |
|
Related Substances |
Individual impurity $\le$ 0.10%; Total impurities $\le$ 0.5% |
|
Assay |
98.5% to 101.5% calculated on the dried basis |
Manufacturing and Supply
Synthesis Route: Liquid-phase and stereoselective catalytic hydrogenation processes ensuring high chiral purity.
Purification Process: Multi-stage crystallization, controlled temperature filtration, and vacuum drying to achieve targeted particle size distribution profiles.
Cleanroom Environment: Isolation, milling, and packaging executed inside ISO Class 8 cleanrooms equipped with continuous differential pressure and high-efficiency particulate air filtration.
Equipment Trains: Reaction trains utilizing glass-lined and stainless steel reactors, automated centrifuge systems, and agitated nutsche filter-dryers.
In-Process Controls: Automated monitoring of pH, temperature, agitation speed, and residual solvent concentrations using gas chromatography and high-performance liquid chromatography.
Supply Capacity: Scalable production capacity ranging from pilot validation batches to commercial multi-metric ton supplies per annum.
Documentation
Regulatory Dossiers: Drug Master File available for global regulatory filing and reference.
Analytical Documentation: Certificate of Analysis issued for every production batch detailing exact assay, impurity levels, and physical parameters.
Compliance Certificates: Written Confirmation for active substances imported into the European Union, Good Manufacturing Practice certificates, and Certificate of Suitability status upon request.
Safety Data: Detailed Safety Data Sheet covering handling, storage, occupational exposure limits, and environmental precautions.
Traceability Records: Complete batch production records, raw material genealogy reports, and analytical raw data available for quality audits.
Packaging
|
Primary Packaging |
Double-layer low-density polyethylene bags heat-sealed under positive pressure. |
|
Secondary Packaging |
Rigid, moisture-tight fiber drums or high-density polyethylene drums containing tamper-evident seals. |
|
Desiccant Integration |
Silica gel packets positioned between primary and secondary layers to prevent moisture degradation during transit. |
|
Standard Dimensions |
Net weight 25 kg per drum with customized configurations available upon validated request. |
|
Labeling Compliance |
Outer drums labeled with product name, CAS number, batch number, manufacturing date, retest date, net weight, gross weight, storage requirements, and hazard warnings. |
Pharmaceutical Application
Essential Hypertension: Formulated into oral tablets for monotherapy or combination therapy to lower systemic arterial blood pressure by decreasing vascular resistance.
Congestive Heart Failure: Utilized as adjunctive pharmacological therapy to reduce cardiac preload and afterload, improving myocardial survival and functional capacity.
Acute Myocardial Infarction: Administered in hemodynamically stable patients within 24 hours of infarction to prevent ventricular remodeling and preserve left ventricular systolic function.
Diabetic Nephropathy: Applied in patients with type 2 diabetes mellitus to lower intraglomerular pressure, mitigate microalbuminuria, and slow the progression of renal disease.
FAQ
Q: What is the standard packaging size for commercial orders of Lisinopril API?
A: The standard export packaging is 25 kg net weight packed in double low-density polyethylene bags sealed inside a high-density polyethylene or fiber drum.
Q: Is a Drug Master File available for regulatory submission?
A: Yes, a comprehensive Drug Master File is maintained and available to support customer regulatory filings across global jurisdictions.
Q: What pharmacopeial standards does this Lisinopril API comply with?
A: The material is manufactured and tested in accordance with United States Pharmacopeia and European Pharmacopoeia monographs.
Q: What are the recommended storage conditions to ensure chemical stability?
A: Store in tightly closed containers at controlled room temperature between 15°C and 30°C, protected from direct exposure to moisture, light, and heat.
Q: What analytical methods are used to control impurity profiles?
A: Related substances and degradation products are quantified using validated high-performance liquid chromatography methods compliant with international guidelines.
Hot Tags: lisinopril, China lisinopril manufacturers, suppliers, factory




